The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDestiny Pharma. Share News (DEST)

Share Price Information for Destiny Pharma. (DEST)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 15.75
Bid: 15.50
Ask: 16.00
Change: -0.50 (-3.08%)
Spread: 0.50 (3.226%)
Open: 16.25
High: 16.25
Low: 15.70
Prev. Close: 16.25
DEST Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: UK stocks rise as Paris and Frankfurt head lower

Thu, 22nd Dec 2022 12:10

(Alliance News) - Stock prices in London were higher at midday on Thursday, ahead of some key US economic data, while equities elsewhere were less buoyant.

The FTSE 100 index was up 34.11 points, 0.5%, at 7,531.43. The FTSE 250 was up 62.80 points, 0.3%, at 18,926.45 , and the AIM All-Share was down just 0.2 of a point, at 830.22.

The Cboe UK 100 was up 0.4% at 752.75, the Cboe UK 250 was up 0.4% at 16,376.71, and the Cboe Small Companies was up 0.1% at 12,933.78.

"The markets seem to be heading into Christmas on a slightly more hopeful note amid signs the US consumer is proving more resilient than feared," said AJ Bell investment director Russ Mould.

This positivity did not extend to European equities, which had fallen into the red by early afternoon Thursday. The CAC 40 in Paris was marginally lower, while the DAX 40 in Frankfurt was down 0.2%.

Consumer confidence in the US economy improved in December, bouncing more than expected as inflation expectations eased and gasoline prices cooled, survey data showed on Wednesday.

The closely watched consumer confidence index rose more than analysts predicted to 108.3 points this month, markedly higher than the revised 101.4 figure in November, said think tank the Conference Board.

There are more US economic indicators to come on Thursday, with US weekly unemployment insurance claims, as well as a gross domestic product print, and personal consumption expenditures.

Annualised US GDP growth is expected to be confirmed at 2.9% in the third quarter.

The dollar was mixed ahead of the data, while stocks in New York were called lower.

Sterling was quoted at USD1.2062 early Thursday, lower than USD1.2093 at the London equities close on Wednesday. The euro traded at USD1.0629, higher than USD1.0612. Against the yen, the dollar was quoted at JPY132.18, firm versus JPY132.08.

The Dow Jones Industrial Average, the S&P 500, and the Nasdaq Composite all were called down 0.3%.

Earlier on Thursday, a new UK GDP print showed a sharper decline in the third quarter than previously forecast.

The UK economy is now estimated to have contracted by 0.3% between July to September. This was downwardly revised from a previous estimate of a 0.2% decline. It mainly reflects revisions to production and construction output estimates, ONS said.

The estimates were adjusted due to the additional bank holiday in September for the state funeral of Queen Elizabeth II, which saw businesses close or reduce their operations.

Meanwhile, annual real UK GDP was revised upwards to 7.6% growth in 2021 from a previous estimate of 7.5%. Despite this, downward revisions in 2022 meant that real GDP is now estimated to be 0.8% below its pre-pandemic size.

This compares with a previous estimate of being just 0.4% below. The estimate shows the UK is the only G7 country to continue to fall short of its pre-pandemic performance.

"There is clearly a caveat in that the UK did shutter shops and close offices and factories to allow people to take time off to pay their respects to the late Queen. But all in all, it's hard to find the silver lining in these gathering storm clouds," said AJ Bell's Danni Hewson.

Gold was quoted at USD1,814.65 an ounce at midday on Thursday, edging down from USD1,815.20 on Wednesday. Brent oil fetched USD83.69 a barrel, higher than USD81.68.

In London, FTSE 100 heavyweights BP and Shell were up 1.7% and 1.0% respectively, tracking the oil price higher.

Amid a more risk-on mood, defensive stocks such as United Utilities and British American Tobacco were succumbing to selling pressure, losing 2.1% and 1.2% respectively.

In the FTSE 250, DiscoverIE was up 1.0%, having returned some of its early morning gain.

The specialised electronic components firm has acquired Magnasphere, a US-based company that designs and manufactures magnetic sensors and switches for industrial electronic purposes. It will pay out USD22 million on a debt-free, cash-free basis before expenses, funded from existing debt facilities.

The acquisition will be immediately accretive to underlying earnings and underlying operating margin, discoverIE said.

"This acquisition of Magnasphere continues our strategy of building a differentiated, international, growth-focused electronics group with strong operating margin," said discoverIE Chief Executive Nick Jefferies.

On AIM, Tekmar surged up 50%.

The offshore energy markets services and technology provider won a new contract to supply cable protection systems to phase three of the UK's Dogger Bank C wind farm. The award comes from DEME Offshore.

The 3.6 gigawatt wind farm is located off the north east coast of England. Tekmar will design, manufacture and supply a further 172 CPS, having already supplied 380 CPS in the A and B project phases at Dogger Bank. It provided no financial details.

Destiny Pharma also added 10%.

The clinical-stage biotechnology company, said the completion of a partnering agreement for its NTCD-M3 phase 3 drug is expected in early 2023.

The company said it had entered exclusive negotiations with a US pharmaceutical company to secure a commercialisation partner for NTCD-M3 - its lead asset for the prevention of clostridioides difficile infection recurrence.

Thursday is the last full day of trading in London before Christmas, before an early finish at 1230 GMT on Friday.

By Elizabeth Winter, Alliance News senior markets reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2022 Alliance News Ltd. All Rights Reserved.

More News
27 May 2021 16:06

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

Read more
14 Apr 2021 12:04

TRADING UPDATES: Quixant swings to 2020 loss but recommends dividend

TRADING UPDATES: Quixant swings to 2020 loss but recommends dividend

Read more
7 Apr 2021 15:58

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
29 Mar 2021 09:59

AIM WINNERS & LOSERS: Destiny Pharma jumps on positive nasal gel study

AIM WINNERS & LOSERS: Destiny Pharma jumps on positive nasal gel study

Read more
29 Mar 2021 09:02

Destiny Pharma jumps as infection-fighting nasal gel shows promise

Destiny Pharma jumps as infection-fighting nasal gel shows promise

Read more
15 Mar 2021 21:44

TRADING UPDATES: Arix backs buyback; 88 Energy notes share price surge

TRADING UPDATES: Arix backs buyback; 88 Energy notes share price surge

Read more
10 Mar 2021 20:22

IN BRIEF: Destiny Pharma CSO joins UK Covid-19 research taskforce

IN BRIEF: Destiny Pharma CSO joins UK Covid-19 research taskforce

Read more
3 Feb 2021 11:09

IN BRIEF: Destiny Pharma Secures Brazilian Patent For XF-73 Nasal Gel

IN BRIEF: Destiny Pharma Secures Brazilian Patent For XF-73 Nasal Gel

Read more
2 Feb 2021 14:34

IN BRIEF: Destiny Pharma Adds Mark Wilcox To Scientific Advisory Board

IN BRIEF: Destiny Pharma Adds Mark Wilcox To Scientific Advisory Board

Read more
6 Jan 2021 14:27

UK EXECUTIVE CHANGE SUMMARY: Martin Gilbert Joins River & Mercantile

UK EXECUTIVE CHANGE SUMMARY: Martin Gilbert Joins River & Mercantile

Read more
5 Jan 2021 21:15

IN BRIEF: Destiny Pharma Completes Recruitment For XF-73 Gel Trial

IN BRIEF: Destiny Pharma Completes Recruitment For XF-73 Gel Trial

Read more
5 Jan 2021 11:21

Destiny Pharma meets recruitment deadline for XF-73 trial

(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma announced on Tuesday that its XF-73 phase 2b clinical trial was fully recruited by 31 December, meeting the target timeline set for the programme.

Read more
22 Dec 2020 18:06

UK TRADING UPDATE SUMMARY: Lekoil Fires Back At Shareholder Metallon

UK TRADING UPDATE SUMMARY: Lekoil Fires Back At Shareholder Metallon

Read more
25 Nov 2020 18:00

UK TRADING UPDATE SUMMARY: SourceBio Tips Jump In Virus Testing Demand

UK TRADING UPDATE SUMMARY: SourceBio Tips Jump In Virus Testing Demand

Read more
9 Nov 2020 17:15

Destiny Pharma Set For GBP11.5 Million Raise To Buy NTCD-M3

Destiny Pharma Set For GBP11.5 Million Raise To Buy NTCD-M3

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.